Antivirals for Influenza A in Children
Oseltamivir is the first-line antiviral for treating influenza A in children, dosed weight-based twice daily for 5 days, and should be initiated as soon as possible regardless of illness duration in hospitalized children or those with severe/progressive disease.
Primary Treatment Recommendations
Oseltamivir Dosing by Weight (≥1 year old)
The weight-based dosing for treatment is 1:
- ≤15 kg: 30 mg twice daily
- >15-23 kg: 45 mg twice daily
- >23-40 kg: 60 mg twice daily
- >40 kg: 75 mg twice daily
- Duration: 5 days (longer courses for patients remaining severely ill)
Infants <1 Year
No antivirals are FDA-approved for infants under 1 year 1. However, under emergency use situations, oseltamivir at 1.0 mg/kg/dose twice daily in premature neonates produces appropriate drug exposures 2.
Who Should Receive Treatment
Treat immediately without waiting for test results:
- All hospitalized children with suspected or confirmed influenza 3
- Children with underlying medical conditions
- Those with severe or progressive symptoms
- High-risk patients with non-severe disease (within 48 hours of symptom onset) 4, 5
Recent evidence shows only 42% of hospitalized children receive appropriate antiviral treatment 6, representing a significant treatment gap. Early treatment reduces illness duration, symptom severity, and risk of complications including hospitalization and death 3.
Alternative Agents
Zanamivir
- Approved for children ≥7 years (treatment) and ≥5 years (prophylaxis)
- Inhaled formulation may be problematic in children with respiratory disease
- Currently susceptible to influenza A strains 1
Baloxavir Marboxil
Recent data shows baloxavir demonstrates superior efficacy in reducing fever clearance time and total illness duration compared to oseltamivir in children aged 10-16 years, with an 84% curative rate versus 45-49% for oseltamivir formulations 7. The WHO conditionally recommends baloxavir for high-risk non-severe cases within 48 hours of symptom onset 4, 5. However, it is more expensive and has a single-dose regimen that may enhance compliance 7.
Peramivir
- Intravenous neuraminidase inhibitor approved by FDA 3
- Useful when oral/inhaled routes unavailable
Chemoprophylaxis Dosing
For exposed contacts at high risk, oseltamivir once daily 1:
- ≤15 kg: 30 mg once daily
- >15-23 kg: 45 mg once daily
- >23-40 kg: 60 mg once daily
- >40 kg: 75 mg once daily
- Duration: 10 days after household exposure; 7 days after other exposures
Critical Resistance Considerations
Adamantanes (amantadine, rimantadine) should NOT be used - influenza A viruses are resistant 1. Oseltamivir and zanamivir remain susceptible, though resistance can develop during treatment (18% in one Japanese pediatric study) 1. Resistance emergence is more common in immunocompromised patients with prolonged viral replication 1.
Common Pitfalls to Avoid
- Don't delay treatment waiting for test confirmation in hospitalized or high-risk children
- Don't apply outpatient guidelines to inpatients - all hospitalized children warrant treatment 6
- Don't use adamantanes - they are ineffective against current strains
- Don't withhold treatment beyond 48 hours - while earlier is better, hospitalized patients benefit even with later initiation 3
- Reduce oseltamivir dose in patients with creatinine clearance <30 mL/min 1
Adjunctive Therapies NOT Recommended
Strong evidence advises against routine use of 4, 5:
- Corticosteroids (conditional recommendation against in severe cases)
- Antibiotics (unless bacterial co-infection documented)
- NSAIDs
- Macrolides
- mTOR inhibitors